Massive/JJ
Identification/NN
of/IN
Cancer-Specific/JJ
Nucleic/JJ
Acid/NN
Ligands/NNS
./.
====================
Targeting/VBG
of/IN
complex/NN
system/NN
such/JJ
as/IN
human/JJ
cells/NNS
rather/RB
====================
than/IN
biochemically/RB
pure/JJ
molecules/NNS
will/MD
be/VB
a/DT
useful/JJ
approach/NN
to/TO
massively/RB
identify/VBP
ligands/NNS
specific/JJ
for/IN
the/DT
markers/NNS
associated/VBN
with/IN
human/JJ
disease/NN
such/JJ
as/IN
cancer/NN
and/CC
simultaneously/RB
discover/RB
the/DT
specific/JJ
molecular/JJ
markers/NNS
./.
====================
In/IN
this/DT
study/NN
,/,
we/PRP
developed/VBD
in/IN
vitro/FW
selection/NN
method/NN
to/TO
identify/VB
nuclease-resistant/JJ
nucleic/JJ
acid/NN
ligands/NNS
called/VBN
RNA/NN
aptamers/NNS
that/DT
are/VBP
specific/JJ
for/IN
human/JJ
cancer/NN
cells/NNS
./.
====================
This/DT
method/NN
is/VBZ
based/VBN
on/IN
the/DT
combination/NN
of/IN
the/DT
cell-based/JJ
selection/NN
and/CC
subtractive/JJ
systematic/JJ
evolution/NN
of/IN
ligands/NNS
by/IN
exponential/JJ
enrichment/JJ
(/(
SELEX/NN
)/)
method/NN
./.
====================
These/DT
aptamers/NNS
will/MD
be/VB
useful/JJ
for/IN
cancer-specific/JJ
ligands/NNS
for/IN
proteomic/JJ
research/NN
to/TO
identify/VB
cancer-specific/JJ
molecular/JJ
markers/NNS
as/IN
well/RB
as/IN
tumor/NN
diagnosis/NN
and/CC
therapy/NN
./.
====================
RNA/NN
can/MD
adopt/VB
stable/JJ
tertiary/NN
structures/NNS
to/TO
specifically/RB
bind/VBP
target/NN
molecules/NNS
with/IN
high/JJ
affinities/NNS
and/CC
specificities/NNS
and/CC
encode/VBP
easily/RB
amplificable/JJ
genetic/JJ
information/NN
./.
====================
Therefore/RB
,/,
RNAs/NNS
could/MD
be/VB
a/DT
very/RB
useful/JJ
agent/NN
for/IN
basic/JJ
research/NN
and/CC
diagnostic/JJ
and/CC
therapeutic/JJ
aims/NNS
(/(
Gold/JJ
et/FW
a/DT
!/JJ
./.
,/,
1993/CD
;/:
Burgstaller/NNP
et/FW
al./FW
,/,
2002/CD
)/)
./.
====================
Such/JJ
RNA/NN
ligands/NNS
with/IN
short/JJ
size/NN
,/,
termed/VBN
RNA/NN
aptamers/NNS
,/,
have/VBP
been/VBN
identified/VBN
for/IN
a/DT
host/NN
range/NN
of/IN
targets/NNS
including/VBG
proteins/NNS
,/,
carbohydrates/VBZ
,/,
and/CC
small/JJ
chemicals/NNS
,/,
etc./FW
,/,
from/IN
a/DT
random/JJ
RNA/NN
library/NN
using/VBG
in/IN
vitro/FW
iterative/JJ
selection/NN
techniques/NNS
,/,
called/VBN
systematic/JJ
evolution/NN
of/IN
ligands/NNS
by/IN
exponential/JJ
enrichment/JJ
(/(
SELEX/NN
)/)
(/(
Ellington/NNP
and/CC
Szostak/JJ
,/,
1990/CD
;/:
Tuerkand/CC
Gold/JJ
,/,
1990/CD
)/)
./.
====================
Recently/RB
,/,
several/JJ
RNA/NN
aptamers/NNS
were/VBD
reported/VBN
to/TO
have/VB
potentials/NNS
of/IN
diagnostic/JJ
ligands/NNS
and/CC
even/RB
therapeutic/JJ
potentials/NNS
from/IN
animal/NN
disease/NN
====================
models/NNS
(/(
Sullengerand/NN
Gilboa/NN
,/,
2002/CD
;/:
Hwang/NNP
etal./FW
,/,
2003/CD
;/:
Rusconi/NNP
etal./FW
,/,
2004/CD
)/)
./.
====================
Targeting/VBG
a/DT
complex/JJ
target/NN
mixture/NN
such/JJ
as/IN
human/JJ
red/JJ
blood/NN
cell/NN
ghosts/NNS
was/VBD
reported/VBN
to/TO
identify/VB
a/DT
pool/NN
of/IN
aptamers/NNS
using/VBG
selection/NN
procedure/NN
,/,
called/VBN
‘/NN
complex/NN
targets/NNS
SELEX/NN
’/CD
(/(
Morris/NNP
et/FW
al./FW
,/,
1998/CD
)/)
./.
====================
Such/JJ
targeting/VBG
of/IN
complex/NN
systems/NNS
rather/RB
than/IN
biochemically/RB
pure/JJ
molecules/NNS
will/MD
be/VB
useful/JJ
to/TO
massively/RB
identify/VBP
specific/JJ
molecular/JJ
markers/NNS
associated/VBN
with/IN
human/JJ
disease/NN
and/CC
simultaneously/RB
identify/VBP
ligands/NNS
specific/JJ
for/IN
the/DT
markers/NNS
without/IN
prior/JJ
knowledge/NN
of/IN
any/DT
molecular/JJ
changes/NNS
associated/VBN
with/IN
the/DT
disease/NN
state/NN
(/(
Daniels/NNS
etal./FW
,/,
2003/CD
)/)
./.
====================
In/IN
this/DT
study/NN
,/,
we/PRP
established/VBD
in/IN
vitro/FW
SELEX/NN
method/NN
which/WDT
is/VBZ
based/VBN
on/IN
the/DT
combination/NN
of/IN
the/DT
cell-based/JJ
selection/NN
with/IN
subtractive/JJ
SELEX/NN
method/NN
for/IN
the/DT
selection/NN
of/IN
nuclease-resistant/JJ
RNA/NN
aptamers/NNS
specific/JJ
for/IN
the/DT
cancer/NN
cell/NN
surface/NN
./.
====================
We/PRP
selected/VBD
RNase-resistant/JJ
RNA/NN
aptamers/NNS
to/TO
specifically/RB
recognize/VBP
the/DT
target/NN
cancer/NN
cell/NN
lines/NNS
,/,
Jurkat/NN
T/NN
leukemia/NN
cells/NNS
,/,
but/CC
not/RB
normal/JJ
peripheral/JJ
blood/NN
mononuclear/JJ
cells/NNS
(/(
PBMC/NN
)/)
./.
====================
A/DT
random/JJ
RNA/NN
library/NN
of/IN
~10/CD
14/CD
different/JJ
molecules/NNS
was/VBD
created/VBN
with/IN
every/RB
pyrimidine/NN
modified/VBN
at/IN
its/PRP$
2/CD
’/CD
position/NN
by/IN
a/DT
fluoro/NN
group/NN
./.
====================
The/DT
sequence/NN
of/IN
the/DT
RNA/NN
library/NN
was/VBD
5/CD
’/NN
-GGGAUACCA/NN
====================
GCUUAUUCAAUUN/NN
6/CD
o/NN
AGAUAGUAAGUGCAAUCU-3/NN
’/CD
,/,
====================
where/WRB
N/NN
6/CD
o/NN
denotes/VBZ
60/CD
nucleotides/NNS
(/(
nts/NNS
)/)
with/IN
the/DT
====================
equimolar/JJ
incorporation/NN
of/IN
A/DT
,/,
G/NN
,/,
C/NN
,/,
and/CC
U/NNP
at/IN
each/DT
position/NN
./.
====================
Therefore/RB
,/,
each/DT
molecule/NN
in/IN
the/DT
library/NN
harbored/VBD
60-nt/JJ
long/JJ
region/NN
derived/VBN
from/IN
a/DT
randomized/JJ
sequence/NN
flanked/VBN
by/IN
defined/VBN
sequences/NNS
./.
====================
The/DT
modification/NN
of/IN
the/DT
2/CD
’/CD
position/NN
of/IN
RNA/NN
improved/VBD
its/PRP$
stability/NN
in/IN
human/JJ
serum/NN
more/RBR
than/IN
10,000/CD
fold/JJ
,/,
when/WRB
compared/VBN
with/IN
unmodified/JJ
2/CD
’/CD
hydroxyl/NN
RNA/NN
(/(
Seo/JJ
and/CC
Lee/NNP
,/,
2000/CD
;/:
Lee/NNP
and/CC
Sullenger/NN
,/,
1996/CD
,/,
1997/CD
)/)
./.
====================
We/PRP
employed/VBD
subtractive/JJ
SELEX/NN
procedure/NN
to/TO
preclude/VB
nonspecific/JJ
RNAs/NNS
that/DT
bind/VBP
to/TO
normal/JJ
cells/NNS
as/IN
follows/VBZ
./.
====================
Five/CD
xzg/VBG
of/IN
the/DT
RNA/NN
library/NN
was/VBD
first/JJ
incubated/VBN
at/IN
37°C/NN
for/IN
1/CD
hr/NN
with/IN
1.5x10/CD
5/CD
of/IN
normal/JJ
PBMC/NN
in/IN
200/CD
pl/NN
of/IN
a/DT
binding/VBG
buffer/NN
(/(
30/CD
mM/NN
Tris-HCI/NN
,/,
pH/NN
7.5/CD
,/,
150/CD
mM/NN
NaCI/NN
,/,
1.5/CD
mM/NN
====================
MgCI/NN
2/CD
,2/NN
mM/NN
dithiothreitol/NN
,/,
and/CC
1/CD
%/NN
BSA/NN
)/)
,/,
and/CC
any/DT
RNAs/NNS
====================
that/DT
had/VBD
bound/VBN
to/TO
the/DT
molecules/NNS
on/IN
the/DT
normal/JJ
cell/NN
surface/NN
have/VBP
been/VBN
discarded/VBN
by/IN
centrifugation/NN
./.
====================
The/DT
====================
precleared/VBN
supernatant/JJ
RNA/NN
pools/NNS
were/VBD
then/RB
reacted/VBD
with/IN
1.5x10/CD
5/CD
of/IN
the/DT
target/NN
Jurkat/NN
cells/NNS
,/,
and/CC
the/DT
leukemia/NN
cell-RNA/JJ
complexes/NNS
precipitated/VBD
./.
====================
Bound/CC
RNAs/NNS
were/VBD
amplified/VBN
and/CC
transcribed/VBD
to/TO
generate/VB
RNA/NN
for/IN
the/DT
next/JJ
cycle/NN
of/IN
selection/NN
,/,
as/IN
previously/RB
described/VBN
(/(
Bae/NN
et/FW
al./FW
,/,
2002/CD
;/:
Lee/NNP
and/CC
Sullenger/NN
,/,
1996/CD
,/,
1997/CD
)/)
./.
====================
The/DT
subtractive/JJ
procedure/NN
was/VBD
performed/VBN
prior/JJ
to/TO
every/DT
selection/NN
round/NN
./.
====================
After/IN
total/JJ
13/CD
rounds/NNS
of/IN
selection/NN
,/,
the/DT
amplified/VBN
cDNA/NN
was/VBD
cloned/VBN
and/CC
sequenced/VBN
./.
====================
Different/JJ
RNAs/NNS
were/VBD
selected/VBN
probably/RB
due/JJ
to/TO
diverse/JJ
target/NN
molecules/NNS
on/IN
the/DT
surface/NN
of/IN
the/DT
Jurkat/NN
cells/NNS
(/(
Fig/NN
./.
====================
1/CD
)/)
./.
====================
To/TO
assess/VB
the/DT
enrichment/JJ
of/IN
the/DT
selected/VBN
RNAs/NNS
,/,
pool/NN
of/IN
amplified/VBN
cDNAs/NNS
of/IN
the/DT
selected/VBN
RNAs/NNS
was/VBD
in/IN
vitro/FW
transcribed/VBN
,/,
and/CC
the/DT
purified/VBN
RNA/NN
(/(
200/CD
ng/NN
)/)
was/VBD
incubated/VBN
with/IN
5x10/CD
5/CD
of/IN
PBMC/NN
or/CC
Jurkat/NN
cells/NNS
./.
====================
The/DT
bound/VBN
RNAs/NNS
were/VBD
then/RB
reverse/JJ
transcribed/VBN
,/,
and/CC
the/DT
resulting/VBG
cDNA/NN
was/VBD
amplified/VBN
(/(
forward/JJ
primer/NN
,/,
====================
5/CD
’/NN
-GGGTAATACGACTCACTATAGGGATACCAGCTT/NN
====================
ATTCATT/NN
:/:
reverse/JJ
primer/NN
,/,
5-AGATTGCACTTACTATCT/NN
)/)
with/IN
10/CD
thermal/JJ
cycles/NNS
./.
====================
The/DT
semi-quantitative/JJ
RT-PCR/NN
analysis/NN
of/IN
the/DT
selected/VBN
RNA/NN
aptamers/NNS
bound/VBD
to/TO
cells/NNS
showed/VBD
that/IN
the/DT
RNAs/NNS
were/VBD
enriched/VBN
specifically/RB
to/TO
the/DT
Jurkat/NN
cells/NNS
(/(
data/NNS
not/RB
shown/VBN
)/)
./.
====================
To/TO
confirm/VB
that/IN
the/DT
pool/NN
of/IN
the/DT
selected/VBN
RNAs/NNS
====================
specifically/RB
bound/VBD
to/TO
the/DT
target/NN
cells/NNS
,/,
flow/NN
cytometry/NN
====================
analysis/NN
was/VBD
performed/VBN
with/IN
FITC-labeled/JJ
aptamers/NNS
(/(
Fig/NN
./.
====================
2/CD
)/)
./.
====================
FITC-labeled/JJ
RNA/NN
aptamers/NNS
were/VBD
prepared/VBN
as/IN
described/VBN
(/(
Rosemeyer/NNP
et/FW
al./FW
,/,
1995/CD
)/)
./.
====================
Briefly/RB
,/,
in/IN
vitro/FW
transcribed/VBN
RNA/NN
aptamers/NNS
(/(
121/CD
pmol/NN
)/)
were/VBD
labeled/VBN
at/IN
their/PRP$
3/CD
’/NN
ends/NNS
by/IN
incubation/NN
with/IN
5X/NN
reaction/NN
buffer/NN
(/(
200/CD
mM/NN
potassium/NN
cacodylate/NN
,/,
25/CD
mM/NN
Tris-HCI/NN
,/,
pH/NN
6.6,0.25/CD
mg/ml/NN
BSA/NN
,/,
0.5/CD
mM/NN
dNTP/NN
)/)
,/,
0.5/CD
mM/NN
FITC-dUTP/NN
====================
(/(
Roche/NNP
)/)
,/,
5/CD
mM/NN
CoCI/NN
2/CD
,/,
and/CC
20/CD
U/NNP
terminal/JJ
deoxynucleotide/NN
====================
transferase/NN
(/(
Roche/NNP
)/)
in/IN
a/DT
final/JJ
volume/NN
of/IN
30/CD
///NN
(/(
'/``
for/IN
30/CD
min/NN
at/IN
37°C/NN
./.
====================
FITC-labeled/JJ
RNA/NN
aptamers/NNS
(/(
30/CD
pmoles/NNS
)/)
were/VBD
then/RB
incubated/VBN
with/IN
1x10/CD
6/CD
normal/JJ
PBMC/NN
or/CC
Jurkat/NN
cells/NNS
./.
====================
FITC/NN
fluorescence/NN
was/VBD
monitored/VBN
using/VBG
FACScan/NN
apparatus/NN
(/(
Becton/NN
Dickinson/NN
)/)
./.
====================
Results/NNS
were/VBD
represented/VBN
as/IN
frequency/NN
distribution/NN
histograms/NNS
of/IN
log/NN
fluorescence/NN
./.
====================
FITC-labeled/JJ
RNA/NN
pools/NNS
after/IN
13/CD
th/DT
round/NN
bound/VBD
more/RBR
strongly/RB
to/TO
Jurkat/NN
T/NN
cells/NNS
,/,
by/IN
about/RB
7-fold/JJ
in/IN
fluorescence/NN
intensity/NN
,/,
than/IN
to/TO
the/DT
normal/JJ
PBMC/NN
./.
====================
By/IN
contrast/NN
,/,
FITC-labeled/JJ
RNA/NN
library/NN
hardly/RB
bound/VBD
to/TO
either/CC
PBMC/NN
or/CC
Jurkat/NN
cells/NNS
(/(
data/NNS
not/RB
shown/VBN
)/)
./.
====================
These/DT
results/NNS
indicate/VBP
that/IN
the/DT
selected/VBN
RNA/NN
aptamers/NNS
specifically/RB
bound/VBD
to/TO
the/DT
Jurkat/NN
T/NN
leukemia/NN
cells/NNS
./.
====================
Recently/RB
,/,
large/JJ
efforts/NNS
are/VBP
focused/VBN
on/IN
the/DT
identification/NN
of/IN
specific/JJ
messages/NNS
associated/VBN
with/IN
a/DT
wide/JJ
range/NN
of/IN
human/JJ
diseases/NNS
including/VBG
cancers/NNS
(/(
Strausberg/NN
etal/JJ
./.
====================
2004/CD
)/)
./.
====================
Conventional/JJ
SELEX/NN
procedure/NN
could/MD
be/VB
conducted/VBN
to/TO
isolate/VB
cancer-specific/JJ
RNA/NN
aptamers/NNS
with/IN
purified/VBN
proteins/NNS
after/IN
expression/NN
of/IN
the/DT
specific/JJ
messages/NNS
./.
====================
However/RB
,/,
an/DT
obvious/JJ
advantage/NN
of/IN
the/DT
cell-based/JJ
subtractive/JJ
SELEX/NN
developed/VBD
here/RB
is/VBZ
that/DT
a/DT
specific/JJ
disease/NN
such/JJ
as/IN
cancer/NN
could/MD
be/VB
targeted/VBN
without/IN
prior/JJ
knowledge/NN
of/IN
any/DT
molecular/JJ
alterations/NNS
related/JJ
to/TO
the/DT
disease/NN
state/NN
(/(
Daniels/NNS
etal./FW
,/,
2003/CD
)/)
./.
====================
Noticeably/RB
,/,
any/DT
nonspecific/JJ
RNAs/NNS
that/DT
can/MD
bind/VB
to/TO
nontargeted/JJ
cell/NN
surface/NN
could/MD
be/VB
easily/RB
eliminated/VBD
by/IN
employing/VBG
in/IN
vitro/FW
preclusion/NN
step/NN
which/WDT
is/VBZ
simply/RB
incubating/VBG
nondesirable/JJ
cells/NNS
and/CC
discarding/VBG
RNAs/NNS
binding/VBG
to/TO
the/DT
cells/NNS
./.
====================
These/DT
aptamers/NNS
can/MD
be/VB
applied/VBN
to/TO
specific/JJ
diagnosis/NN
,/,
imaging/VBG
,/,
and/CC
therapy/NN
of/IN
tumor/NN
(/(
Lupoid/NN
et/FW
al./FW
,/,
2002/CD
)/)
./.
====================
Moreover/RB
,/,
characterization/NN
of/IN
molecular/JJ
targets/NNS
against/IN
the/DT
RNA/NN
aptamers/NNS
will/MD
be/VB
of/IN
important/JJ
use/NN
to/TO
identify/VB
novel/JJ
specific/JJ
molecular/JJ
markers/NNS
of/IN
the/DT
cancer/NN
./.
====================
